Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Hospital Pedro Hispano Northwestern University |
---|---|
Information provided by: | Hospital Pedro Hispano |
ClinicalTrials.gov Identifier: | NCT00114491 |
Recent studies support the hypothesis that aortic stenosis (AS) develops due to atherosclerosis affecting the aortic valve endothelium. The study’s aim was to assess Rosuvastatin on the hemodynamic progression and inflammatory markers of AS by treating low-density lipoprotein (LDL) in patients with AS according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATPIII) guidelines for one year.
Condition | Intervention | Phase |
---|---|---|
Atherosclerosis Hypercholesterolemia |
Drug: Rosuvastatin |
Phase IV |
Study Type: | Observational |
Study Design: | Natural History, Longitudinal, Defined Population, Prospective Study |
Official Title: | Rosuvastatin Affecting Aortic Valve Endothelium - RAAVE |
Estimated Enrollment: | 200 |
Study Start Date: | September 2003 |
Estimated Study Completion Date: | May 2005 |
Background: Recent retrospective studies support the hypothesis that statins slow the progression of aortic stenosis. The aim of this study was to assess the effect of Rosuvastatin on hemodynamic progression of aortic stenosis by treating patients with aortic stenosis and elevated LDL-cholesterol for 18 months.
Methods: We performed an open-label, prospective study evaluating 121 consecutive patients with asymptomatic moderate to severe aortic stenosis (AVA≥ 1.0 cm2), (mean age 73.7±8.9 years; 57 men and 64 women), treated with and without Rosuvastatin according to the NCEP-ATPIII guidelines. Echocardiographic, serum lipid, and inflammatory markers were measured at baseline and every 6 months for 18 months.
Ages Eligible for Study: | 50 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 22352 |
Study First Received: | June 15, 2005 |
Last Updated: | October 30, 2006 |
ClinicalTrials.gov Identifier: | NCT00114491 |
Health Authority: | Portugal: National Pharmacy and Medicines Institute |
Aortic Stenosis Statins Hypercholesterolemia |
Atherosclerosis Arterial Occlusive Diseases Hyperlipidemias Metabolic Diseases Vascular Diseases Constriction, Pathologic Arteriosclerosis |
Aortic valve stenosis Rosuvastatin Aortic Valve Stenosis Metabolic disorder Hypercholesterolemia Dyslipidemias Lipid Metabolism Disorders |
Antimetabolites Molecular Mechanisms of Pharmacological Action Therapeutic Uses Antilipemic Agents Enzyme Inhibitors |
Cardiovascular Diseases Anticholesteremic Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors Pharmacologic Actions |